共 50 条
Revealing the molecular mechanism of baohuoside I for the treatment of breast cancer based on network pharmacology and molecular docking
被引:1
|作者:
Mu, Junjie
[1
]
Li, Ying
[1
]
Chen, Qiuxiong
[1
]
Xiao, Yujie
[1
]
Hu, Min
[1
]
He, Ziyue
[1
]
Zeng, Jun
[1
]
Ding, Yiling
[3
]
Song, Pengyang
[4
]
He, Xiao
[5
]
Yang, Xian
[1
]
Zhang, Xue
[2
]
机构:
[1] Chongqing Normal Univ, Engn Res Ctr Biotechnol Act Subst, Minist Educ, Chongqing 401331, Peoples R China
[2] Chongqing Med & Pharmaceut Coll, Chongqing 401331, Peoples R China
[3] Pengshui Cty Forestry Bur, Chongqing 409600, Peoples R China
[4] Wansheng Econ & Technol Dev Zone Planning & Nat Re, Chongqing 400800, Peoples R China
[5] Chongqing Three Gorges Med Coll, Chongqing 404120, Peoples R China
关键词:
Breast cancer;
Baohuoside I;
Network pharmacology;
Molecular docking;
EGFR inhibition;
Cell apoptosis;
TRADITIONAL CHINESE MEDICINE;
PATHWAY;
CELLS;
D O I:
10.1016/j.jep.2024.118918
中图分类号:
Q94 [植物学];
学科分类号:
071001 ;
摘要:
Ethnopharmacological relevance: In Traditional Chinese Medicine (TCM), there are many prescriptions for treating breast cancer (BC) that utilize the herb Epimedium brevicornum Maxim, which warms and replenishes kidney yang. Baohuoside I (BI) is a flavonoid compound found in Epimedium brevicornum Maxim. As a single glycoside, it is not easily hydrolyzed in the intestine and is typically absorbed as a precursor. As a natural product with potential anti-cancer properties, studies have shown that BI possesses anti-cancer activity and can inhibit the invasion and migration of BC cells. However, its underlying mechanisms remain unclear, thus further research is needed to validate its modern mechanisms for traditional uses. Aim of the study: This study aimed to explore the regulatory mechanism of BI in the signaling pathways of BC cells through network pharmacology (NP), molecular docking (MD) techniques and cellular experiments. Methods: Potential targets were predicted using public databases, and a protein-protein interaction (PPI) network was constructed. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed. Key signaling pathways were validated through MD techniques, cellular experiments, RNA interference and Western blot (WB) analysis. Results: Treatment-associated targets included SRC, MAPK1, HSP90AA1, PIK3CA, TP53, AKT1, and EGFR. GO enrichment, KEGG enrichment analyses, and MD results indicated that BI exerts its anti-breast cancer effects by inhibiting the tyrosine kinase activity of EGFR, as well as through downstream MAPK signaling pathway and PI3K-Akt signaling pathway pathways. In vitro experiments confirmed that BI primarily induce cell apoptosis through the EGFR-mediated MAPK signaling pathway and PI3K-Akt signaling pathway. Conclusion: BI can inhibit EGFR activation and promote BC cell apoptosis through the MAPK signaling pathway and PI3K-Akt signaling pathway, thereby exerting therapeutic effects on BC. This study not only provides
引用
收藏
页数:12
相关论文